DEC1 Antibody - BSA Free

Flow Cytometry: DEC1 Antibody - BSA Free [NB100-1800]

Flow Cytometry: DEC1 Antibody - BSA Free [NB100-1800] - An intracellular stain was performed on A431 cells with DEC1 Antibody NB100-1800AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.

Western Blot: DEC1 Antibody - BSA Free [NB100-1800] - DEC1 expression decreases in HeLa cells under apoptosis. Western blotting images of cleaved-poly (ADP-ribose) polymerase (PARP), cleaved-caspase 3, Bcl-2, DEC1, DEC2, SOX2, c-MYC and actin treated with 10, 20, and 50 uM cisplatin or mock in HeLa and SiHa cells. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33089188/) licensed under a CC-BY license.

Western Blot: DEC1 AntibodyBSA Free [NB100-1800]

Western Blot: DEC1 Antibody - BSA Free [NB100-1800] - Western blot analysis of DEC1 in HeLa whole cell lysate.

Immunohistochemistry-Paraffin: DEC1 Antibody - BSA Free [NB100-1800]

Immunohistochemistry-Paraffin: DEC1 Antibody - BSA Free [NB100-1800] - P. gingivalis-challenged rat maxilla using DEC1 antibody at 1:100. Heat mediated antigen retrieval (sodium citrate buffer pH 6.0) was performed. Counter-stained with hematoxylin. Image from verified customer review.

Immunoprecipitation: DEC1 Antibody - BSA Free [NB100-1800]

Immunoprecipitation: DEC1 Antibody - BSA Free [NB100-1800] - Samples: Whole cell lysate from HeLa (50 ug for WB) and 293T (1 mg/IP, 20% of IP loaded) cells. Antibodies: Affinity purified rabbit anti-DEC1 antibody BL2928 used for WB at 0.1 ug/ml (A) and 1 ug/ml (B) and for IP at 3 ug/mg lysate. DEC1 was also immunoprecipitated using rabbit anti-DEC1 antibodies BL2926 and BL2927, which recognize upstream epitopes. Detection: Chemiluminescence with exposure times of 3 minutes (A) and 30 seconds (B).

Simple Western: DEC1 AntibodyBSA Free [NB100-1800]

Simple Western: DEC1 Antibody - BSA Free [NB100-1800] - Simple Western lane view shows a specific band for DEC1 in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Immunoblotting: DEC1 Antibody - BSA Free [NB100-1800]

Immunoblotting: DEC1 Antibody - BSA Free [NB100-1800] - (B) HSC-2 cells were used to perform knockdown assays for three primary antibodies: HIF1A, DEC1, and DEC2 9. Real-time RT-PCR evaluated expression levels of MSH2, MBD4, MRE11A, BRCA1, and RAD51. Value displayed above the bar represents the ratio of expression under hypoxic conditions compared with that under normoxia. Citation: Nakamura H, Bono H, Hiyama K, Kawamoto T, Kato Y, Nakanishi T, et al. (2018) Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions. PLoS ONE 13(2): e0192136. https://doi.org/10.1371/journal.pone.0192136

Immunoblotting: DEC1 Antibody - BSA Free [NB100-1800]

Immunoblotting: DEC1 Antibody - BSA Free [NB100-1800] - DNA-DRR genes promoter activities decreased with DEC. (B) The DEC1 or DEC2 expression plasmids (B), each reporter, and DEC1 or delta basic DEC1 expression plasmids (C) were co-transfected into HepG2. Under normoxic conditions they were then incubated for 36 hours. A dual-luciferase assay system determined luciferase activities. Citation: Nakamura H, Bono H, Hiyama K, Kawamoto T, Kato Y, Nakanishi T, et al. (2018) Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions. PLoS ONE 13(2): e0192136. https://doi.org/10.1371/journal.pone.0192136

Immunoblotting: DEC1 Antibody - BSA Free [NB100-1800]

Immunoblotting: DEC1 Antibody - BSA Free [NB100-1800] - Knockdown assays in HSC-2 cells for HIF1A, DEC1, and DEC2. After transfecting and culturing non-specific siRNA or targeted siRNA into HSC-2, culturing them under normoxic and hypoxic conditions (24 hours), RT-PCR evaluated expression levels of the three primary antibodies. Citation: Nakamura H, Bono H, Hiyama K, Kawamoto T, Kato Y, Nakanishi T, et al. (2018) Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions. PLoS ONE 13(2): e0192136. https://doi.org/10.1371/journal.pone.0192136

Detection of DEC1 in A431 Human Cell Line by Flow Cytometry.

A431 human skin carcinoma cell line was stained with Rabbit anti-DEC1 Affinity-purified Polyclonal Antibody conjugated to Phycoerythrin (Catalog # NB100-1800PE, blue histogram) or matched control antibody (Catalog # NBP2-24983, orange histogram).

Immunohistochemistry: DEC1 Antibody - BSA Free [NB100-1800] -

Immunohistochemistry: DEC1 Antibody - BSA Free [NB100-1800] - Dec1 expression is increased in the myocardial cells of cardiac hypertrophy & myocardial infarction. Immunohistochemical detection of Dec1 in human cardiac diseases. Representative image of Dec1 immunoreactivities from case 1 to case 8. Case 1 (control) had no significant findings (NS). Cases 2 to 6 are cardiac hypertrophy (CH). Case 7 is acute myocardial infarction (AMI), & case 8 is an old myocardial infarction (OMI). Magnification 400×. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31597354), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: DEC1 Antibody - BSA Free [NB100-1800] -

Western Blot: DEC1 Antibody - BSA Free [NB100-1800] - DEC1 has anti-apoptotic effects in HeLa cells under apoptosis. (A) Cell viability of HeLa, SiHa & Caski cells with (+) or without (−) cisplatin & empty vector, DEC1 or DEC2 plasmid treatment was determined. The absorbance (OD480/OD650) at 0 & 24 h is shown. The value of cell viability of control 0 h regarded as 10. Data are expressed as mean values ± SE (bars) of three independent samples. * p < 0.05, as determined using t-test. (B) Western blotting images of DEC1, DEC2, cleaved-PARP, cleaved-caspase 3, Bcl-2, beta-catenin, SOX2, c-MYC & actin treated with 50 μM cisplatin & empty vector, DEC1 or DEC2 plasmid in HeLa cells. Western blot analysis was repeated three times & similar results were obtained. (C) SOX2 & c-MYC mRNA expressions in HeLa & SiHa cells with cisplatin & empty vector, DEC1 or DEC2 plasmid treatment. Data are expressed as mean values ± SE (bars) of three independent samples. * p < 0.01, as determined using t-test. qPCR was repeated three times & similar results were obtained. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33089188), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: DEC1 Antibody - BSA Free [NB100-1800] -

Immunohistochemistry: DEC1 Antibody - BSA Free [NB100-1800] - Immunoreactivities of DEC1, DEC2, SOX2, c-MYC & vimentin in cervical cancer tissues. Representative images for the immunoreactivities of DEC1, DEC2, SOX2, c-MYC & vimentin in cervical cancer tissues. Each panel shows ×200 magnification. DEC1 immunoreactivities in (A) non-cancerous cells, (B) shallow cancer cells, & (C) deep cancer cells of case 14. DEC1 immunoreactivity in (D) SCC of case 1, & in (E) AC of case 5, respectively. DEC2 immunoreactivities in (F) non-cancerous cells, (G) & cancer cells of case 15. SOX2 immunoreactivities in (H) non-cancerous cells, (I) shallow cancer cells, & (J) deep cancer cells of case 14. c-MYC immunoreactivities in (K) non-cancerous cells, (L) & cancer cells of case 15. Vimentin immunoreactivities in (M) non-cancerous vascular cells, (N) & cancerous vascular cells of case 14. Black arrows in E-G show nuclear staining. The white arrow in E indicates non-cancerous cells. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33089188), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: DEC1 Antibody - BSA Free [NB100-1800] -

Western Blot: DEC1 Antibody - BSA Free [NB100-1800] - DEC1 expression decreases in HeLa cells under apoptosis. (A) Endogenous DEC1 protein expressions in HeLa & SiHa cells. Western blotting images of beta-catenin, DEC1, DEC2, SOX2, c-MYC & actin in HeLa & SiHa cells. The western blot analysis was repeated three times & similar results were obtained. (B) Cell viability of HeLa & SiHa cells with (+) or without (−) cisplatin treatment was determined. The absorbance (OD480/OD650) at 0 & 24 h is shown. The value of cell viability of control 0 h regarded as 10, which means each basal value without treatment. Data are expressed as mean values ± SE (bars) of three independent samples. * p <0.01, as determined using Dunnett’s test. Cis: Cisplatin treatment. (C) Western blotting images of cleaved-poly (ADP-ribose) polymerase (PARP), cleaved-caspase 3, Bcl-2, DEC1, DEC2, SOX2, c-MYC & actin treated with 10, 20, & 50 μM cisplatin or mock in HeLa & SiHa cells. The western blot analysis was repeated three times & similar results were obtained (D) DEC1, DEC2 & SOX2 mRNA expressions in HeLa & SiHa cells with (+) or without (−) cisplatin treatment. Data are expressed as mean values ± SE (bars) of three independent samples. * p < 0.01, as determined using t-test. qPCR was repeated three times & similar results were obtained. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33089188), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: DEC1 Antibody - BSA Free [NB100-1800] -

Immunohistochemistry: DEC1 Antibody - BSA Free [NB100-1800] - Immunoreactivities of DEC1, DEC2, SOX2, c-MYC & vimentin in cervical cancer tissues. Representative images for the immunoreactivities of DEC1, DEC2, SOX2, c-MYC & vimentin in cervical cancer tissues. Each panel shows ×200 magnification. DEC1 immunoreactivities in (A) non-cancerous cells, (B) shallow cancer cells, & (C) deep cancer cells of case 14. DEC1 immunoreactivity in (D) SCC of case 1, & in (E) AC of case 5, respectively. DEC2 immunoreactivities in (F) non-cancerous cells, (G) & cancer cells of case 15. SOX2 immunoreactivities in (H) non-cancerous cells, (I) shallow cancer cells, & (J) deep cancer cells of case 14. c-MYC immunoreactivities in (K) non-cancerous cells, (L) & cancer cells of case 15. Vimentin immunoreactivities in (M) non-cancerous vascular cells, (N) & cancerous vascular cells of case 14. Black arrows in E-G show nuclear staining. The white arrow in E indicates non-cancerous cells. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33089188), licensed under a CC-BY license. Not internally tested by Novus Biologicals.